Study title: PEDS I PEDIATRIC EPLERENONE DEVELOPMENT STUDY I): A RANDOMIZED, DOUBLE-BLIND, PLACEBO WITHDRAWAL, PARALLEL GROUP, DOSE-RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EPLERENONE IN THE TREATMENT OF HYPERTENSION IN CHILDREN
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Cardiovascular Diseases [C14] | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: EPLERENONE | |||||
| ATC code: C03DA04 | |||||
| Document link: A6141001 PhRMA Clinical Study Synopsis.pdf | |||||
| Document date: 2013-04-16 | |||||
| Study number: A6141001 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |